Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp
Bullboard Posts
User Avatar Image
(25)
•••
Comment by PutinKhuylo1on Sep 07, 2016 2:00pm
165 Views
Post# 25214632

RE:RE:RE:RE:New Sirona twitter post

RE:RE:RE:RE:New Sirona twitter postThere are relatively scientific methods out there by which to come up with a valuation for SBM. Several of us have actually gone thru the numbers previously on this board. Just for the heck of it again - we're being told 1067 is worth $240 million US in an outright sale of 1067 ($1.70C per share). SGLT2 ROW licensing, $100 million US (conservatively, adding another .70C per share).
Glycoproteins? How many are identified? 12? 14? Licensing each or groups = ?US$.
Proprietary fluorination technology? $100US million? $500US million?
Though I personally don't have the exact numbers, there are outfits out there that put numbers to these sorts of things. I've participated in a few biotech IPO's here in the US, and I can't see this going as a package under $5 per share. Just MHO. 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities